Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A construction method and application of ctla4 gene humanized animal model

An animal model and construction method technology, applied in the construction of CTLA4 gene humanized animal model, the application field of biomedicine, can solve the problems of toxic reaction, limit the research and development and application of anti-human CTLA4 antibody, etc.

Active Publication Date: 2021-01-05
GEMPHARMATECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But at the same time, severe clinical toxic side effects led to the emergency suspension of clinical trials. More than half of the patients treated with Ipilimumab had severe side effects of grade 3-4, leading to toxic reactions in the skin, pituitary and intestinal tract, which limited the ability of anti-human CTLA4 Antibody development and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A construction method and application of ctla4 gene humanized animal model
  • A construction method and application of ctla4 gene humanized animal model
  • A construction method and application of ctla4 gene humanized animal model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1: Establishment of CTLA4 humanized mouse model

[0049] Using CRISPR Cas9 to replace Exon2 of the human CTLA4 gene with Exon2 of the mouse Ctla4 gene, a CTLA4 gene humanized mouse model was established. C57BL / 6 mice are currently a relatively mature mouse strain, and C57BL / 6 mice were used as background mice to successfully obtain a CTLA4 humanized mouse model.

[0050] (1) Determine the replacement region of the human fragment and the inserted human sequence

[0051] According to the binding functional domain of human CTLA4 and B7 protein, Exon2 of human CTLA4 sequence was selected to replace Exon2 of mouse Ctla4, and the sequence of mouse Ctla4 signal peptide, transmembrane region and intracellular region was retained. The selected human CTLA4 gene sequence is SEQNo. .1 shown.

[0052] (2) Screening of sgRNA prepared from CTLA4 humanized mice

[0053] Design sgRNA targeting murine sequence in the humanized replacement region. Design and synthesize sgRNA s...

Embodiment 2

[0080] Example 2: Expression and functional verification of CTLA4 humanized mouse model

[0081] 1. Verification of mRNA expression in CTLA4 humanized mice

[0082]Detect the transcription of human CTLA4 in heterozygotes by mRNA, and then analyze the expression of humanized CTLA4 gene in heterozygotes and homozygotes by flow cytometry and check the immune cell population. After analysis, CTLA4 humanized mice can be successfully Humanized CTLA4 mice that express the human CTLA4 gene and do not cause obvious abnormalities in the immune system of the mice can be used for subsequent tumor drug efficacy experiments.

[0083] The detection method is as follows: the samples used in the experiment are humanized CTLA4 (KI / wt) and C57BL / 6 wild type (wt / wt) mice. Extract mouse spleen and thymus RNA for RT-PCR, and sequence the PCR products to verify whether the splicing of CTLA4mRNA is correct. Primers (CTLA4-KI-mRNA-F1, CTLA4-KI-mRNA-R1) are located outside the 5-terminus of murine CT...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the fields of animal gene engineering and genetic modification and particularly relates to an establishment method of a CTLA4 gene humanized animal model and an application thereof. In the invention, the extracellular domain of mouse CTLA4 gene is replaced by a human-source sequence while the intracellular domain holds a complete mouse-source sequence. The CTLA4 gene humanized animal model not only can be used for evaluating the efficacy on tumors of antibodies and has important guiding significance on clinical effect of medicine development, but also is an excellent model for security evaluation on anti-human CTLA4 antibody medicines. The establishment method also includes pre-clinical in-vivo evaluation on the toxicology of the CTLA4 antibody medicine, thus filling market gap.

Description

technical field [0001] The invention belongs to the technical field of animal genetic engineering and genetic modification, and relates to a method for constructing a CTLA4 gene humanized animal model based on CRISPR / Cas9 technology and its application in biomedicine. Background technique [0002] Complex biological processes often require in vivo analysis, and the study of human in vivo biology is severely constrained by ethics and technology, so animal models are increasingly required for in vivo studies of human cells, tissues, and organs. Currently, scientists have developed a variety of humanized mice or human-mouse chimeras to overcome these limitations and have now become important tools for in vivo studies of human cells and tissues. [0003] During the research and development of clinical drugs, mice are widely used in the preclinical safety and effectiveness evaluation of candidate drugs, such as the in vivo effectiveness evaluation of new antiviral drugs, tumor im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113C12N15/90C12N15/12A01K67/027
CPCA01K67/0276A01K2207/15A01K2217/075A01K2227/105A01K2267/0331C07K14/70521C12N15/113C12N15/902C12N2310/10C12N2310/20
Inventor 琚存祥赵静马秀英张明坤侯欢欢高翔
Owner GEMPHARMATECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com